Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia

NCT07352800 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral Arterial Occlusive Disease
Chronic Limb-Threatening Ischemia

Interventions

DRUG: APAC - dose level 0.50 mg/kg,
OTHER: Unfractionated heparin (UFH)
DRUG: APAC dose level 1: 0.25 mg/kg,
OTHER: Vehicle (sterile saline, NaCL 0.9%)
DRUG: APAC dose level 2: 0.50 mg/kg,
DRUG: APAC (single periprocedural dose)
DRUG: APAC

Sponsor

Aplagon Oy

Collaborators

[object Object]
[object Object]